RS
INZY

R Squared’s Inozyme Pharma INZY Stock Holding History

R Squared’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,550
Closed -$18.1K – 878
2024
Q4 		$18.1K Buy
+6,550
New +$24.9K 0.02% 927

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

R Squared's INZY Position: Q1 2025 in Review

R Squared sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 6,550 shares — an estimated $18.1K sold.

R Squared first reported a position in INZY in Q4 2024 and held it in 1 quarter. The position peaked at $18.1K in Q4 2024. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • R Squared reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • R Squared sold 6,550 Inozyme Pharma shares in Q1 2025, an estimated $18.1K.
  • R Squared first reported a position in Inozyme Pharma in Q4 2024 and held it in 1 quarter.
  • R Squared's Inozyme Pharma position peaked at $18.1K in Q4 2024.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.